List of Medical Device Companies with Phase 2 Active Clinical Trial - 230

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR). We are the first transcatheter MR therapy that directly addresses mitral regurgitation without replacing the native mitral valve, thus preserving the native mitral annulus and left ventricle. The device is positioned supra annular to the leaking native mitral valve to stop the leak from entering the left atrium. Its atrial only fixation ensures minimal disruption to critical cardiac structures within the left ventricle including the chordae tendineae and the left ventricular outflow tract. Our initial focus is to develop a novel therapy for mitral regurgitation (MR), and subsequently for tricuspid regurgitation (TR).

Based in Danvers, Massachusetts, USA, Abiomed, Inc., part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com. Important Safety Info: https://bit.ly/39kvb47

Acandis GmbH is a medical technology company based in Pforzheim, Germany, founded in 2006. It focuses on developing, manufacturing, and marketing products for the treatment of neurovascular diseases, particularly in acute and preventive stroke treatment. The company is recognized for its innovative approach and has been named one of the TOP 100 most innovative SMEs in Germany multiple times. Acandis offers a variety of high-tech medical devices, including thrombectomy devices for removing blood clots, embolisation devices to block abnormal blood flow, stents to keep arteries open, and catheter systems for minimally invasive procedures. These products are developed in collaboration with healthcare professionals to ensure they meet clinical needs effectively. With a dedicated team of around 107 employees, Acandis aims to expand its reach internationally, providing essential tools for stroke prevention and therapy to endovascular specialists.

Acorai is developing a device for heart failure management through non-invasive cardiac and pulmonary pressure sensing, to help reduce hospitalizations and readmissions. Our product can monitor cardiac and pulmonary pressure sensing non-invasively through a machine-learning analysis of pressure dynamics in acoustics, vibratory, and waveform data. Our technology shows compelling precision, has a low-risk clinical and regulatory pathway, a low dependence on reimbursement, and a fast track to commercialization.

Adient Medical is a medical devices company that specializes in absorbable devices that automatically vanish, eliminating the need for removal procedures.

Admetsys is a biomedical technology company specializing in critical care automation. The company's flagship PrecisionOne system is the first fully automated glycemic control system and continuous blood diagnostics platform for hospital care. The company was founded to commercialize the next generation of medical automation technology: continuous real-time biosensing, robotics, artificial intelligence and learning algorithms, intelligent therapeutic delivery, and advanced data telemetry.

AB is proud to be the only U.S. based manufacturer of cochlear implants and equally proud to be a part of the larger Sonova group. At AB, success begins with a passion for hearing restoration and is driven by our global workforce of over a thousand employees. For more than 25 years, AB has removed limitations for those otherwise isolated from the world of sound. Always focused on bringing meaningful change through innovative technology, AB has set the standard for performance, lifestyle support, and access to sound in the field of cochlear implantation. Having implanted over 100,000 ears in over 130 countries and established a track record for developing high-performing, state-of-the-art products, our team of talented scientists, engineers, audiologists and other professionals are driven to succeed, work with integrity, and stay firmly committed to quality. Sonova companies include brands focused on hearing aids, cochlear implants, wireless communications, and clinical service. Together, we strive to create a world where everyone enjoys the delight of hearing and lives a life without limitations.Advanced Bionics is a global leader providing solutions for severe-to-profound hearing loss.

Nasal breathing is a very important function of human life and any obstruction in the nasal airway also known as a congested or blocked nose, can dramatically impact the quality of life.The VIVAER treatment, performed in a doctor’s office, is a non-invasive procedure without any incisions. The patient'snasal valve area is gently reshaped using low-temperature radiofrequency energy with lasting results.

Affluent Medical est un nouvel acteur français de la medtech ayant pour ambition de devenir un des leaders européens dans les domaines cardiovasculaires et urologiques. Affluent Medical développe des implants innovants mini-invasifs de nouvelle génération pour restaurer des fonctions physiologiques essentielles dans ces domaines : - Kardiozis vise à prévenir les endofuites et les risques de récidive de l'anévrisme de l'aorte abdominale permettant aux patients de vivre plus sereinement face à un risque de rupture imprévisible ; - Kalios et Epygon visent à offrir des traitements chirurgicaux plus physiologiques pour la réparation ou le remplacement de la valve mitrale du cœur. Kalios permet de traiter les fuites résiduelles post-opératoire et l'insuffisance mitrale récurrente sans avoir à réopérer les patients. Epygon est aujourd'hui la seule valve transcathéter en développement permettant de restaurer les flux sanguins naturels et de sauvegarder le ventricule gauche. - Enfin, Artus est le premier sphincter artificiel activable électroniquement pour traiter l'incontinence urinaire d'effort des hommes et des femmes. Nos avancées technologies permettent d'offrir des dispositifs médicaux qui respectent davantage la physiologie du corps humain. Nos implants sont mis en place grâce à un chirurgie mini-invasive et visent à limiter les risques de récidive précoce ou tardif de la maladie. Les trois prothèses innovantes et la technologie d'Affluent Medical sont en phase sont préclinique ou clinique.

We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com

Alleviant Medical is a medical device company developing next-generation therapies for heart failure.

Founded in 1994, AlloSource is a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients. The company has grown into one of the largest tissue networks in the country creating more than 200 types of precise bone, skin and soft-tissue allografts for use in an array of life-saving and life-enhancing medical procedures. As a leading manufacturer of cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource’s products bridge the proven science of allografts with the advanced technology of cells. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO.

ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through innovation. ATEC’s Organic Innovation Machine™ is the greatest concentration of spine knowhow in the industry and committed to the creation of clinical distinction. Leveraging 100% spine focus and expertise, we seek to improve spine surgery by rethinking, redesigning and seamlessly integrating the technologies required from the ground up. The innovation that results from that process is being rapidly adopted because, like us, spine surgeons covet informatic and procedural sophistication that enables more predictable, more reproducible care. Our flagship technology, the Prone TransPsoas (PTPTM) Procedure, leveraged decades of experience to advance first-generation lateral surgery with a more familiar patient position and elevated neuromonitoring.   EOS imaging, the backbone of ATEC’s informatic ecosystem, provides radiographic imaging, enabling standing, full-body, global alignment assessments. We are further developing EOS technology to elevate spine care with unprecedented capabilities. Our vision is to be the standard bearer in spine. Visit our website for more information: www.atecspine.com

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally restore normal physiological function in women suffering with mixed urinary incontinence. The company's first therapy, Amber UI, is an intelligent closed-loop bioelectrical therapy for urge and mixed urinary incontinence. The startup has also acquired Bioinduction, a fellow U.K.-based company and the maker of the Picostim DyNeuMo platform.

Innovations that make a difference Ever since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring solutions. In the past, we provided a way to maintain or restore breathing in any environment with the world's first self-inflating resuscitator, the Ambu® Bag™, which is still in use today. More recently, we responded to a need for an endoscopy solution that is always available. The result? Ambu® aScope™, the world's first sterile, single-use flexible endoscope. Today, we continue to collaborate with leading medical experts to deliver innovations that make a real difference to healthcare professionals and their patients. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America and the Asia Pacific, 4,500+ team members keep Ambu moving forward. Ambu – Forever Forward For more information, please visit www.ambu.com

Amnio Technology is an industry leader in the development and manufacture of amnion-derived technologies. Amnio Technology manufactures high-quality, amnion-derived technologies for clinical use.

AVS is an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2018 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. We are redefining interventional therapy for severely calcified lesions with our Pulse IVL System, which uses a novel pulsatile mechanism of action to shatter calcium and expand narrowed vessels, all with a single device. To learn more about pulsatile intravascular lithotripsy, visit www.avspulse.com.

AMRA Medical is a health informatics company founded in 2010, originating from Linköping University in Sweden. With a team of over 30 employees and a global presence, AMRA specializes in AI-driven medical imaging and precision medicine, particularly in advanced MRI analytics for body composition assessment. The company has achieved regulatory clearances, including CE-Marked medical device status, and collaborates with major industry players like Pfizer Inc. AMRA offers next-generation phenotyping that utilizes AI to analyze whole-body MRI scans, providing precise fat and muscle biomarkers for personalized health insights. Their cloud-based platform ensures secure, quality-controlled results with a quick turnaround and is compatible with various MRI scanners. The company also develops imaging biomarkers and disease phenotypes through partnerships, aiming to create a global representative database. Under the leadership of CEO Eric Converse and co-founders Magnus Borga and Olof Dahlqvist Leinhard, AMRA focuses on equipping clinicians and researchers with actionable data to manage conditions such as obesity and metabolic disorders.

Aria CV, Inc: Improving the lives of patients suffering from the disease of pulmonary hypertension.

ARTCLINE GmbH develops innovative therapy methods for intensive care medicine based on immune cells. Our current main project is the development of the so-called ARTICE technology for the treatment of bacterial sepsis. ARTCLINE's vision is the development of innovative immune cell-based therapy approaches and to make the technology available to physicians and hospitals worldwide. The safety and effectiveness of the therapy is our top priority. Our extensive cell biological, clinical and industrial experience in the fields of immunology, sepsis diagnostics and therapy help us to realize our vision. Together with scientists and partners, we focus our research activities on the root causes and correlations of sepsis. For many years, the founders and the team of ARTCLINE GmbH have been successfully involved in the transfer of medical inventions from university research to industrial application. We have an extensive network and long standing experience in the development and successful marketing of medical devices and drugs.

ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform, intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.

Artivion is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseases—coupled with our recent acquisitions and partnerships—have empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts, surgical sealants, prosthetic heart valves, and aortic stents and stent-grafts. Artivion has over 1,250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta, Georgia, Austin, Texas, and Hechingen, Germany. Additionally, it has sales and distribution offices in various countries throughout Europe, Asia, and South America.

The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atreon Orthopedics is a tissue regeneration company powered by breakthrough regenerative technology and renowned scientific expertise. Tendon and ligament injuries affect ten million people yearly, spanning all lifestyles and demographics. Atreon is committed to dramatically improving healing and long-term outcomes for patients encountering these soft-tissue injuries. ROTIUM®, our initial product for rotator cuff repair, is a bioresorbable wick designed as a scaffold to harness and hold biologically active substances at the repair site providing a pro-healing environment that promotes healthy tissue and native tissue regeneration. Recently published human and animal studies and over 10,000 cases have shown a safe and effective solution to improving biology, restoring function, and improving rotator cuff success rates.

Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox imaging console, the Ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in PAD patients.

Developing seamless neural interfaces.

Axonics Modulation Technologies, Inc is a privately-held medical device company developing an innovative neuromodulation platform based on miniaturized rechargeable technology. The Axonics Sacral Neuromodulation System™ is the first CE-marked rechargeable SNM system designed to improve the experience of both clinicians and patients suffering from Urinary and Fecal dysfunction (not available in the US).

Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 100,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

Bioretec Ltd. is a medical device company focusing on the development of strong, safe and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. Our products are used worldwide, and we continue to further develop materials and products for load-bearing clinical applications.

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient product for triage and monitoring of disease progression.

BlueWind Medical is a medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has successfully completed several clinical studies and is focused on bringing this breakthroughRENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market.

BONESUPPORT AB is a Scandinavian orthobiologics company based in Lund, Sweden, specializing in advanced bone graft solutions. Founded in 1999, the company develops and commercializes bioceramic products aimed at managing bone injuries. Its flagship product, CERAMENT®, is an injectable bioceramic material designed for bone void filling and infection management, featuring osteoconductive properties and drug-eluting capabilities for localized antibiotic delivery. The company operates globally, achieving net sales of SEK 899 million in 2024, with significant growth in both North America and Europe. BONESUPPORT focuses on direct commercialization in key markets and partnerships for global distribution. The leadership team includes experienced executives in business administration and orthobiologics, with a strong emphasis on clinical validation and innovative solutions for orthopedic surgeons, trauma centers, and hospitals.

Boomerang Pharmaceutical Communications marry the art of creativity with the rigor of science to produce outstanding digital solutions for the pharmaceutical and biotech industries. Their in-house experts cover every dimension of digital communication. They have all the tools, skills and knowledge needed to craft a comprehensive digital strategy

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS.

Breathe BioMedical® is developing an innovative breath analytics platform to enable the early detection of disease. Our proprietary breath analytics technology is designed to collect, process and analyze breath samples to identify biomarker patterns associated with specific diseases. Breathe BioMedical is focused first on implementing a new breath test for breast cancer detection for women with dense breast tissue, as an adjunct to mammography, with the goal of increasing the number of breast cancer cases identified at the earliest stages. One day, detecting disease may be as easy as breathing.

Bright Uro is an early-stage medical technology company headquartered in Irvine, CA. They are building the next generation of diagnostic devices for Urology.

Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for chronic and acute pain. Their Neural Ice™ has the potential for long-lasting pain control from one injection, intended to eradicate the pain of pain.

CairnSurgical, Inc. is a clinical stage medical device company developing patient-specific surgical guides using patient imaging data and state-of-the-art 3D printing technologies. CairnSurgical's Breast Cancer Locator System enables precise tumor localization and excision, and has been tested in both single-arm and randomized clinical trials. The Breast Cancer Locator is considered an investigational device in the U.S. and is limited by U.S. law to investigational use only. It is not approved for sale in any region.

Cala kIQ is a healthcare technology company that specializes in digital therapeutics and medical devices.

Caldera Medical is a medical device company solely focused on women's health with a commitment to our mission of "Improving the Quality of Life for Women!" We develop, build and market best in class surgical products for the treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse. Working closely with surgeons to help those here at home, as well as women around the world, through our humanitarian programs to give them the access to the education and treatment they deserve. Mission - To Improve the Quality of Life for Women Vision - To be the Global Leader in Women's Pelvic Health Values "C4"​ - Care / Collaborate / Challenge / Create

Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones, a common and painful condition that consumes vast amounts of healthcare resources today. Founded in 2016, Calyxo is led by executives and investors with a strong track record of commercializing paradigm-shifting solutions in the field of urology. Our team features some of the most talented, high-achieving and brightest minds in the medical device industry who are compelled by a desire to make a difference in kidney stone care. We are proud of our collaborative, diverse, fun and dynamic culture. We drive our actions based on our core values which we call ‘F.I.T to WIN.’ Find Joy: We celebrate wins and enjoy the journey! Integrity: We are truthful, honorable, and reliable. Transparency: We share what’s going on in our business. We are open, honest and have a clear communication across our organization. Win as a Team: We are earnest collaborators. We hold ourselves and each other accountable.

At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.

Caption Health has been acquired by GE HealthCare. Follow us at @GEHealthCare and @CaptionCare for the latest updates and healthcare news.

CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AFib), the most common heart arrhythmia. The company's FDA-approved HeartLight Endoscopic Ablation System has successfully treated more than 10,000 patients in the United States, Europe and Japan. The HeartLight System is a revolutionary catheter ablation technology that along with direct visualization and titratable laser energy, represents a new standard for AFib ablation. CardioFocus is headquartered in Marlborough, MA. For more information, visit www.CardioFocus.com. Social Media Community Guidelines: bit.ly/2IDIBZR

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

Clear Guide Medical is a leader in next-gen medical imaging fusion and navigation technology. Our vision-based approach has been introduced in a family of clinical guidance products, including the CLEAR GUIDE SCENERGY for instrument guidance and SCENERGY FUSION for ultrasound and CT/MRI image fusion. Our products make minimally-invasive interventions like biopsies, ablations, pain injections, and peripheral nerve blocks efficient and cost-effective. The company is a privately-held spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University based in Baltimore, Maryland.

CoapTech is bringing a series of breakthrough medical devices to worldwide markets, leveraging a patented, disruptive platform technology called the Point-of-care Ultrasound Magnet Aligned (PUMA) System. The PUMA Platform will disrupt multiple medical procedures, reducing health care costs, and improving efficiency, safety, quality, patient experience, and access to services around the globe. Invented by Dr. Steven Tropello, a Johns Hopkins-trained critical care physician, the PUMA System enables diagnostic, interventional and therapeutic procedures in hollow organs. The system combines magnetic attraction for device placement guidance, and ubiquitous, low-cost, point-of-care ultrasound for visualization in hollow cavities. Our lead device, the PUMA-G, selected because of its low risk, clear FDA pathway, and strong commercial viability, is for the insertion of Gastrostomy (feeding) tubes. PUMA-G enables a point-of-care (i.e. bedside, as opposed to operating room) procedure for inserting gastrostomy tubes which can be quickly and easily performed by non-surgical providers. By eliminating specialty suites and specialist consultants, PUMA-G will save hospitals money and improve efficiency and safety for this common procedure. PUMA-G has been validated in human anatomy, and has a streamlined regulatory pathway based on FDA presubmission feedback.

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Collagen Matrix is a biotechnology company that specializes in developing medical devices and products for regenerative medicine using collagen as a key component.

Comphya is a Swiss medical device company, spin-off from the Swiss Federal Institute of Technology (EPFL). Its mission is to overcome the major clinical problems of erectile dysfunction (ED) in spinal cord injury and post-prostatectomy patients (non-responders to oral drugs). Our innovation lies on neuroprosthetics principles and will offer a unique and superior treatment for ED. Our goal is to fulfill patient needs through safe and effective medical devices, offering life quality in large parts of the male population in great need.

Conformal Medical develops medical devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology will help left atrial appendage closure meet its true potential.

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

At Cook, we are building our future on Invention, Connection, People, and Community. As a privately owned company, we can look at the world our own way and do what we feel passionate about. What are we passionate about? That’s simple: Making unique, quality products and connecting with people to improve lives on both sides of the device. Central to our focus on building deep connections is our belief in the importance of identifying innovative solutions to help customers, patients, employees, and communities thrive. We understand that our ongoing success will come from creating inclusive, supportive, and healthy environments where we can prosper together. Our people are our greatest asset and are at the heart of everything we do. Come build with us.

Patented, Drug-Free, Faster, and More Effective Treatment for Vaginal Infections. Powered by Project Medtech.

Cordis is a medical devices company that specializes in cardiology equipment and healthcare technology.

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance.

Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.

CorWave is a French company developing innovative cardiac assist devices. CorWave's wave membrane pump is a breakthrough technology that differs from today's commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave's membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up studio MD Start and is funded by renowned investors including Bpifrance, Exor Ventures, EIC Fund, Financière Arbevel, M&L Healthcare, Novo Holdings, Seventure Partners, Sofinnova Partners, Ysios Capital and Vlerick Group. The company has secured over €80 million in equity and employs over seventy people.

At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. Our integrated electrosurgery unit delivers Bipolar Radiofrequency for precise dissection and resection and Microwave energy for controlled ablation and coagulation. This technology sets a new standard for Endoscopic Submucosal Dissection with our new Speedboat RS2 instrument: the Bipolar Radiofrequency cut allows precise dissection and the microwave coagulation provides controlled haemostasis while the protective hull reduces the risk of muscle damage and the integrated injection needle helps to maintain submucosal lift without instrument changes.

Cryosa is a clinical stage company developing a treatment for moderate to severe Obstructive Sleep Apnea (OSA). We believe that mask-free, hose-free, implant-free treatment is possible. Everyone is free to sleep, free to rest and free to live brighter days.

CVRx is a commercial stage, public (NASDAQ: CVRX) medical devices company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. Barostim™ triggers carotid baroreceptors - the body's own natural blood flow regulation system - which signals the brain to regulate cardiovascular function. Patient Stories on CVRx: The accounts and quotes of patients are genuine and documented. These stories represent a unique individual experience and does not provide any indication, guide, warranty or guarantee as to the response other people may have to CVRx technologies. Barostim is a prescriptive device. For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/

Cynosure is a leader in the medical devices industry specializing in aesthetic medicine and cosmetic procedures.

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d'Études et de Recherches pour l'Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

Diality, Inc. is a privately held medical device company based in Irvine, California, focused on improving the lives of individuals affected by kidney disease. The company is dedicated to transforming the dialysis landscape by promoting personalized and cost-effective care models, moving away from traditional centralized facilities. Diality is developing the Moda-flx, a versatile hemodialysis system designed to be simple, mobile, and intelligent. This system allows healthcare professionals to provide personalized dialysis treatments in various settings while maintaining high-quality care. The Moda-flx is user-friendly, reducing training time for clinicians, and features secure data storage and cloud accessibility to support data-driven decision-making. The company is a member of the Advanced Medical Technology Association (AdvaMed) and adheres to its Code of Ethics. Diality has also joined Kidney Care Partners and secured significant investments, including a $24 million Series B2 funding round, highlighting its commitment to innovation in kidney care.

We are a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows.  Powered by a culture of continuous improvement, extraordinary talent and innovation, we ‘create better together' by partnering with healthcare professionals. Our extensive range of products, services and integrated technologies fuel active lifestyles. 

Medical device sales/distribution organizations needed for a non-narcotic chronic pain treatment solution develop by DyAnsys Inc. Be a part of a billion-dollar market. This innovative solution has tremendous growth potential with the current focus on reducing the use of narcotics for pain treatment. DyAnsys Inc. has been growing rapidly and needs to expand its coverage of the U.S. market. Distributors who are already working in the pain management field and have a base of pain management clients are preferred. Successful candidates should: • Have been in the medical device sales and distribution business for at least five years. • Have a sales force or access to 1099 reps to assure full territory coverage. • Be able to focus on DyAnsys products to grow the business rapidly. To learn more: Call 1-888-950-4321 or e-mail new.distributor@dyansys.com DyAnsys Inc. is a global company, headquartered in the Silicon Valley (California, USA), and is led by a worldwide team of professionals drawn from the medical, mathematical and IT fields who are working hard to make DyAnsys a worldwide leader in providing advanced medical diagnostic and monitoring systems to clinicians in individual practices and hospitals. By using sophisticated mathematical analysis of the ECG and other electrical signals, DyAnsys applications focus on chronic and acute pain, anesthesia, diabetes, and fetal heart monitoring.

Dynocardia is a biomedical device development company committed to satisfying critical unmet needs to improve healthcare worldwide. ViTrack™, our lead diagnostic device, is powered our proprietary technology making it the only stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. Unlike conventional occlusive devices, ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable, mobile, and easy to use, with the accuracy of intra-arterial lines. ViTrack, with data-rich capability that includes heart rate, heart rhythm, and respiratory parameters in addition to blood pressure, enables early intervention prior to acute events.

EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/ Explore a directory of our most popular content https://linktr.ee/echonous.kosmos

Echosens is a healthcare technology company that specializes in non-invasive diagnostic tools for assessing liver health.

The company works with doctors to develop medical devices related tostructural heart disease and critical care monitoring.

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable. Ekso Bionics is headquartered in San Rafael, California International Offices: Ekso Bionics Europe GmbH Friesenweg 20 Hamburg, 22763 Germany Tel: +49 40 800 4049 20

In 2005, we were founded on a unified belief that neuromodulation could be used in novel ways to help patients break free from treatments they aren’t happy with. Because different modalities of neuromodulation had previously proven to be effective and safe, we recognized an opportunity to be the leader in this new frontier of medicine and took it head on. Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop safe and clinically backed treatments. Bringing new treatments to market will help improve patients'​ treatment options and lives.

ElmediX is an oncology company committed to develop innovative medical technologies that can boost conventional anticancer therapies through Hyperthermal Therapy. Our main goal is to increase patient quality of life and survival. Our HyperTherm platform is a semi-automated, real-time system which offers accurate, highly-reliable and sensitive temperature control of the patient during treatment. A software-based technology is responsible for an accurate thermal mapping of the patient’s body; this guarantees that the temperature remains within a safe range during treatment. We have an ongoing clinical trial investigating the safety of thermal therapy in advanced solid cancer patients. The trial focuses on patients who do not respond to current standard therapies, patients with cancer types not adequately addressed by available therapies or patients that refuse standard of care treatment. For more information about the clinical trial, please use the following link: https://clinicaltrials.gov/ct2/show/NCT04467593?cond=Pancreatic+Cancer&cntry=BE&draw=2&rank=5 For more information about ElmediX, please check our website: www.elmedix.com

Empatica is an affective computing company, focused on human data analytics. We develop groundbreaking wearable devices with medical quality sensing. Our technology comprises a set of wristband, software running on smartphone and desktop computing, plus real time syncing with a cloud computing service.

We are a team of engineers and physicians based in Hayward, California. We're developing PillBot™, a moving pill-sized camera that will enable 220+ million people around the world to get quick, easy endoscopies at home. Our dream is to save millions of lives through the early detection of cancer, ulcers, and more.

Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex's innovations focus on resetting the body's metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression. Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. We have a therapeutic portfolio designed to treat diseases which currently have clinically relevant unmet needs. Our existing products can treat a wide spectrum of vascular disease through abdominal aortic aneurysms to lower limb peripheral vascular disease. We obtain excellent clinical outcomes through meticulous attention to product design, manufacturing, and training, all backed by industry-leading clinical evidence. With a robust pipeline of disruptive technology, our vision is to provide physicians with the best device for each patient; because when it comes to ensuring patient well-being, we are never satisfied with the status quo.

Endovascular Engineering, Inc. ("E2"), is a mission driven, venture-backed company focusing on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism.

Enovis is a data analytics company that provides technology solutions for business intelligence and information management.

Enspire DBS Therapy, in partnership with Cleveland Clinic and Boston Scientific, is developing a proprietary deep brain stimulation (DBS) therapy to restore motor function for stroke survivors living with disability. Enspire is currently sponsoring EDEN, a Phase I clinical trial of DBS therapy for stroke recovery.

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

Exero Medical's mission is to empower health care providers with high-quality, actionable post-operative tissue healing data that can save lives, improve prognosis, and reduce cost of care. The company's flagship product, the xBar system, has been granted Breakthrough Device Designation by the FDA.

Femasys is a biomedical company focused on transforming women's healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys' FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician's office setting.

Overactive bladder (OAB) affects over 15 million women in the US. The sudden, urgent desire to pass urine greatly limits quality of life. Current treatments are not optimal, requiring frequent, time-consuming office visits, awkward vaginal probes, medications with potential side effects or surgery. Those suffering with OAB often consider the therapies too cumbersome and forgo treatment, opting instead to place limits on their life to accommodate the symptoms. Neuromodulation for OAB involving electrical stimulation of the sacral nerve is a proven and established therapy. However, despite being commercially available for over a decade only a small fraction of indicated patients have been treated. The cost and invasiveness of the surgery are often cited as concerns by prospective recipients. FemPulse has developed a novel, wearable medical device designed to deliver neuromodulation therapy directly to the nerves that regulate bladder function, without the need for surgical implant. The small device is easily placed by the patient herself and controlled with a smartphone app. The company is currently conducting clinical evaluations in the United States.

At Ferrer, we focus on identifying projects with differential value. The R&D team aims to develop and deliver transformative therapeutic solutions for people living with severe and debilitating diseases. Innovation is an inherent part of our pharmaceutical development, and we have always upheld our commitment in searching for and developing new treatment alternatives aimed at addressing unmet medical needs in order to improve the patients' quality of life and creating value for physicians, health systems and society at large. We do this in two main areas: Pulmonary vascular and interstitial lung diseases & Neurological disorders

Ferronova is an innovative medical device company, which has brought together a patented magnetic probe from the University of South Australia and iron magnetic nanoparticle technology from Victoria University of Wellington, to produce an advanced diagnostic system to improve the detection of cancer metastases. Ferronova has research collaborations with UniSA Future Industries Institute, the University of Sydney, and the University of New South Wales. Founded in 2016, Ferronova is backed by Uniseed, Artesian Ventures, ASX-listed investment group Powerhouse Ventures, PAN Ventures, UniSA Ventures and Wellington UniVentures. The South Australian government and Australian government have provided grant funding to develop the technology.

Our cutting-edge technology provides medical professionals with real-time monitoring of renal output, a crucial vital sign that aids in the assessment of a patient's hemodynamic status in various clinical settings, including operating rooms and critical care units. By utilizing our solution, healthcare providers detect and address potential complications promptly, reducing hospitalization-related complications and saving lives.

Fractyl Health is a leader in creating innovative therapies to address the root cause of type 2 diabetes. We were founded based on groundbreaking research and biological insights showing the key role of the intestine in metabolic control. Our therapies are uniquely designed to target and control this controller for the treatment of metabolic disease. Our lead program, Revita DMR, is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes. Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease.

Francis Medical is developing minimally invasive treatment solutions for prostate, kidney, and bladder cancer through the use of convective thermal water vapor. Currently, the company is in clinical trials for ablating cancerous prostate tissue. Founded in 2018, Francis Medical is located in Maple Grove, Minnesota. Francis Medical, Inc., formerly named NxPhase Medical, Inc., is a company that was created after Boston Scientific (BSC) acquired NxThera, Inc. in April of 2018. As a part of the BSC/NxThera transaction, a separate and independent entity, NxPHASE Medical, Inc. (“NxPHASE”), was established, and shares of NxPHASE were distributed to the shareholders of BSC/NxThera. In addition, BSC/NxThera granted NxPHASE a license to utilize BSC/NxThera’s convective vapor ablation technology to develop, evaluate, and commercialize certain devices to treat prostate, kidney and bladder cancer (“NxPHASE Field of Use”), while BSC/NxThera remains focused on the treatment of benign prostatic hyperplasia. Late in 2018, NxPhase Medical, Inc. went through a rebranding process and selected Francis Medical, Inc. as its new brand and identity. The name and foundation of the company are a tribute to and legacy of Michael Hoey’s (founder/inventor) father, Francis Hoey, whose life was ended by prostate cancer with treatments that had harsh implications on his normal daily living.

Genetesis is a rapidly growing medical imaging company leveraging data science and biomagnetism in the fight against cardiovascular disease.

GI Windows Surgical is a clinical-stage company engineering less invasive solutions for surgeons and patients.

Leveraging our deep experience in stroke medicine and bio-engineering, we have developed the world's most powerful and cost-effective solutions to save millions of lives impacted by ischemic stroke

Guided is a Georgia-based medical technology company that develops and commercializes non-invasive medical devices for early detection of cancer.

Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow's footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care. For more information, visit www.heartflow.com.

Helsinn is a global pharmaceutical company that builds, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology, and dermato-oncology. Founded in 1976, Helsinn has over 40 years of experience in the pharmaceutical industry, with an extensive network of long-standing trusted partners enabling a commercial presence in 190 countries. Helsinn Healthcare SA, headquartered in Lugano (Switzerland), oversees the activities of the three Helsinn Group’s subsidiaries (Helsinn Birex Pharmaceuticals Ltd., Helsinn Therapeutics (U.S.), Inc., Helsinn Pharmaceuticals (Beijing) Co., Ltd.), defining and implementing the Group’s strategy. Our mission is to champion and support patients with cancer and chronic diseases at every stage of their journey, by providing them with the best medications and solutions based on their needs and preferences. Follow our LinkedIn page to stay updated with news from Helsinn Group! If you are interested in joining us, please visit our website (www.helsinn.com): applications should only be submitted via the appropriate country portal, available under “Careers – Join us” website section. * This account shall only be used to share news concerning Helsinn. We would like to emphasize that due to the highly regulated nature of the pharma industry, we cannot engage with you online in any discussions concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional.

Hemerion is a clinical stage HealthTech company. Its first breakthrough technology jointly designed with University of Lille, Inserm and University Hospital of Lille, addresses brain cancer and aims to help patients in their fight against glioblastoma. Hemerion results of over 10 years of leading academic and clinical researches on innovative approaches to treat Glioblastoma. Today, Hemerion owns a unique and disruptive technology, already evaluated in frontline approach to treat patients harboring brain cancer.

HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company's new platform delivers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of today's interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.

Inbrain Neuroelectronics is a Neuroelectronics company that specializes in high density and high resolution graphene intelligent neural systems for central and peripheral neuroelectronic applications, with FDA breakthrough Designation.

InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. InfraScan Inc.'s patented NIR technology for diagnosing brain hematomas enables neurosurgeons to effectively, conveniently, and accurately detect intracranial bleeding in patients with Head Trauma.

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer's, Parkinson's or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

InnovHeart, with locations in Milan, Italy, and Boston, Massachusetts, develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. The company is currently in clinical trials testing its novel TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve. Saturn is a low-profile prosthetic designed for both Trans-apical and Trans-septal delivery. Our company mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology. InnovHeart is committed to pursuing this goal with the highest level of quality.

InspireMD is a commercial-stage medical device company with proprietary and innovative stent designs with integrated embolic prevention systems (EPS) designed for delivering neurovascular protection and stroke prevention. InspireMD is dedicated to the development of advanced technologies and seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes through a proprietary stent platform, CGuard™ EPS. CGuard brings to the world the only carotid stent platform with patented MicroNet™ mesh technology designed to reduce stroke during and after CAS. InspireMD (NSPR) is traded on NASDQ Capital Markets.

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.

Invenio Imaging is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative histologic imaging with artificial intelligence. Our technology, the NIO® Laser Imaging System has been used in over 2500 cancer treatment procedures at major cancer centers both in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator and received CE Mark to commercialize in Europe.

JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.

At Kestra, we stand for patients at-risk and the people who care for them. Together we work to protect, support, and empower them with wearable technologies, tools, and better answers as they navigate life's most challenging medical events. Cardiovascular disease is the number one cause of death globally. We're taking a fresh approach to cardiac monitoring and delivery of definitive therapy with wearable products and applications. We aim to make the entire recovery process easier for patients by bringing comfort and assurance to them—along with advanced clinical insights and tools to their medical care teams. Kestra is a privately held, Bain Capital portfolio company, headquartered in Kirkland, Washington USA. Visit us at www.kestramedical.com

KOELIS has assisted urologists and radiologists from around the world in their routine clinical practice since 2006, providing the latest technology for personalized prostate cancer planning and management, from biopsy to active surveillance and treatment. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving quality of life. Thanks to cutting-edge imaging tools like Trinity® cartographer, which combines multiple imaging modalities with full 3D ultrasound, any suspicious lesion is characterized in a detailed 3D prostate map, offering a comprehensive and multiparametric approach and enhancing diagnostic confidence. The team at KOELIS innovates every day in collaboration with world-renowned universities and hospitals to offer physicians new advancements in imaging and a greater field of view, a must-have in active surveillance and targeted treatment. Based in Grenoble and Princeton, KOELIS technology has been featured in more than 50 clinical publications and treats more than 300,000 patients worldwide, including patients in Europe, United States, Canada, Japan, Australia, South America and the Middle East.

Kuros Biosciences is a biotechnology company that specializes in providing superior biologics for better spinal fusions.

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. The company is listed on NASDAQ.

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

Liberate Medical is a medical device company that develops neuromuscular electrical stimulation technology to improve the quality and reduce the cost of care for patients with pulmonary disorders. Liberate's lead product, the VentFree™ respiratory muscle stimulator. Invasive mechanical ventilation commonly weakens the breathing muscles, increasing the need for further ventilator support. VentFree applies proprietary, non-invasive, electrical stimulation to the expiratory muscles in synchrony with exhalation while a patient is on mechanical ventilation. This breakthrough therapy, which is quick and simple to use, is intended to reduce abdominal muscle atrophy and the time taken to liberate patients from mechanical ventilation. Reduced days on mechanical ventilation can potentially lead to reduced morbidity and mortality, improved quality of life, and considerable savings for the health care provider.

The first health wearable monitoring glucose non-invasively. New health insights are unlocked through real time combination of signals. Precision glucose measurements without piercing the skin. This is a world's first. Why glucose? Small irregularities in glucose metabolism compound over time. The progression from healthy to disease is often imperceptible. Awareness is a powerful tool for prevention.

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN." LivaNova has approximately 2,900 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova is a worldwide leader in cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.

Locate Bio bring together Programmed Drug Release and Instructive Tissue Scaffolds to develop the next generation of products with significant disruptive potential for musculoskeletal conditions.

Lumenis creates and commercializes innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. We have successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. Lumenis has a rich history of defying technological boundaries, redefining standards within our domains, and transforming people's lives - both inside and out. Our drive for innovation stems from an uncompromising commitment to providing best-in-class technologies and solutions designed to achieve excellent results. Lumenis has a solid global footprint in developed and emerging markets and sales in over 100 countries. Headquartered in Israel and with offices on four continents, our team consists of nearly 1,500 professionals worldwide.

Luminate Medical is a healthcare technology company that builds devices to make cancer care better for patients by preventing side effects and making at-home treatments a possibility. Based in Galway, Ireland, Luminate is pioneering the development of Lily, a device to prevent chemotherapy induced hair loss in a comfortable and portable way, Lilac, the world's first preventative treatment for peripheral neuropathy, and further pipeline projects enabling remote cancer care. Luminate is a VC-backed startup funded by Y Combinator (S21) with multiple successful grant and investment rounds to date.

Materna Medical is a novel OBGYN platform company defining a $6B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical's mission is to empower women to protect their pelvic health.

MED Institute accelerate product development. MED Institute is dedicated to bringing new medical device products to market that are safe and effective for patients. From concept to commercialization, our team has the knowledge and experience to guide your products through the complex steps required for market approval.

Melodi Health offers novel technologies that improve patient outcomes for women undergoing breast surgery. Melodi Health manufactures the Melodi Matrix, designed to support the soft tissue space around a prosthetic device while delivering antibiotics to the surrounding tissue. The Melodi Matrix is currently an investigational device being studied in a prospective, multi-center, randomized, controlled clinical trial in breast reconstruction.

Meril's core objective is to design, manufacture and distribute clinically relevant, state-of-the-art and best-in-class medical devices to alleviate human suffering and improve quality of life. We thus have a strong commitment towards R & D and adherence to best quality standards in Manufacturing, Scientific Communication and Distribution known today. Origin Established in 2006, Meril was launched in line with the health-care diversification plan by a large format Indian multi-national company. Disclaimer: Information on Meril Digital / Social Media platform is not intended to be a substitute for professional medical advice, diagnosis or treatment. Meril does not recommend self-management of health issues. For more information, visit: https://www.merillife.com/disclaimer

As a global healthcare company, we understand customer needs and innovate and deliver medical solutions that transform patient care. Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 6,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.

Miracor Medical SA is a European medical device company dedicated to improve clinical outcome of patients with impaired cardiac function. Miracor develops and studies the PiCSO® (Pressure-controlled intermittent Coronary Sinus Occlusion) Impulse System, which is used as an adjunctive technique during the primary PCI procedure for acute myocardial infarction patients. PiCSO therapy seeks to improve coronary microvascular function to reduce infarct size and salvage myocardium, thereby improving outcomes of ST-elevation myocardial infarction (STEMI) patients. Recent Clinical Studies have successfully demonstrated the safety and positive effects of PiCSO on coronary microvascular function and infarct size reduction in STEMi patients. The company is conducting further clinical trials in Europe and plans to initiate a US IDE randomized controlled trial in 2023. Miracor has won several innovation awards and completed financing rounds raising venture capital and public funding. The company was founded in May 2008 by Professor Dr. Dr. Werner Mohl and the European venture capital firms Earlybird and Delta Partners.

MolecuLight Inc. a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden > 10^4 CFU/g (when used with clinical signs and symptoms) and for digital wound measurement #moleculight

Momentis Surgical (formerly Memic Innovative Surgery) is a medical device company founded in 2013 and based in Tel Aviv, Israel with a wholly owned subsidiary based in Fort Lauderdale, Florida. Momentis is dedicated to transforming the field of robotic surgery by developing innovative small footprint, cost-effective, robotic-assisted technologies and techniques for a growing number of clinical applications. Our goal is to empower surgeons to perform minimally invasive, complex procedures, enabling better patient outcomes, lowering cost of care, and opening access to more surgeons, patients, hospitals, and surgery centers across the globe. Community Guidelines: https://www.momentissurgical.com/social-media-guidelines/

Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options.

At Neuralace Medical, we are driven to accelerate the world's transition to sustainable, non-invasive chronic pain relief. What do we believe that very few others do? We fundamentally believe that overcoming chronic pain is inevitable. With our bold vision, we are challenging the conventional thinking the healthcare industry is currently laden with to implement innovations and technological advances to improve the overall quality of life of individuals by maximizing pain relief and minimizing side-effects, redefining the very concept of pain therapy which can leave patients with more side-effects than benefits. NeuraLace is not just a device developer, but also a technology company with a focus on medical innovations that can significantly restore the quality of life patients suffering from chronic pain. Our inherent interest in innovation and deep technical knowledge, along with the partnerships we are currently developing, will allow us to realize our vision and create something truly special. We are a startup medical technology company here to make a dent in the world of pain therapeutics!

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

Neurotrigger develops the next generation wearable powered muscle re-education stimulation system. Re-educating muscles is important for facilitating and improving muscle performance and muscle's range of motion, and for the prevention or retardation of disuse atrophy.

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges! Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier.

Building Brain Computers Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca'​ Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics and biotechnologies.

Their vision is to develop clinically validated ‘therapeutic wearables’ that allow for medical devices to become a true alternative to pharmaceuticals in the management of chronic neurological disorders.

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology). We have established deep roots throughout Europe, and more recently, expanded outside of Europe, with the creation of an affiliate in Canada. Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care. Nordic Pharma's values of Commitment, Ambition, Respect, Reliability, Integrity and Agility describe our culture and standards and guide us in our way of working.

Nova Biomedical is a company dedicated to using advanced technology to develop better blood testing analyzers for medical use. These products are called in vitro diagnostic devices (IVD). We use some of the same advanced technology to provide the biotechnology industry with innovative instruments for cell culture monitoring. Nova is the largest privately owned IVD company in the U.S. and the third largest in the world, with over 1,200 employees globally. Our eight percent compounded annual growth over nearly a decade is more than double the IVD market growth, making Nova one the fastest growing IVD companies in the world. Corporate Commitment to Quality Nova's size and rapid growth are the result of customers throughout the world responding to the exceptional quality and value of Nova's technology, products, and customer service. Our strong corporate commitment to these three areas has made Nova a world leader in clinical, veterinary, and biotechnology chemistry testing analyzers. A Leader in Medical Science Technology Maintaining leadership in any technology industry requires a long-term perspective and commitment to research and development. Nova Biomedical has consistently invested more than 10 percent of sales into research and development — more than double the industry average. Our investment in research and development provides a continuous product pipeline of new and better technology products for our customers. Working at Nova Biomedical We practice our core values of mutual respect, honesty, and integrity throughout Nova. With a strong sense of family in the workplace, we are proud that one third of all our employees have been with us for over 10 years.

Novian Health is a late-stage development medical device company based in Chicago, with a subsidiary, Novian Health SAS, in France. Novian Health has developed Novilase, a minimally invasive alternative to lumpectomy for the treatment of breast tumors using Interstitial Laser Therapy (ILT). Novian Health has received a CE Mark for focal destruction of malignant and benign breast tumors, the first thermal ablation device to be approved for breast cancer. Novian Health’s technology enables breast surgeons and radiologists to ablate tumors with image-guided laser therapy. Novilase offers significant advantages over surgery including fewer retreatments, quicker recovery, less pain and fatigue, minimal scarring, and only requires local anesthesia. Novian will conduct a multicenter pivotal trial to evaluate Novilase® laser therapy as a treatment for early-stage breast cancer. U.S. market clearance for the focal destruction of malignant tumors will be sought. Novian will begin commercialization in Europe. Novian Health has received U.S. FDA 510(k) clearance for the treatment of fibroadenomas, or benign breast tumors, and ablation of soft tissue. A registry has been initiated to collect additional information on benign breast tumors treated at centers around the U.S. www.novianhealth.com www.novilase.com

Novostia is a privately held medical device company developing an innovative artificial heart valve, designed for patients of any age, including children. Novostia endeavors to advance its technology to clinical trials and regulatory approvals to improve the quality of life of millions of people worldwide suffering from aortic and mitral valve disease. For more information please visite www.novostia.com

We are Nuwellis, (Nasdaq: NUWE) formerly CHF Solutions. Our solutions go beyond chronic heart failure, so we've rebranded to reflect our therapeutic focus areas: heart failure, critical care, and pediatric fluid imbalance. We are a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. Our Aquadex SmartFlow® System gently removes fluid from adult and pediatric patients weighing 20 kg or more. Nuwellis consists of a purpose-driven team that puts patients and their providers at the center of everything we do. This is the new well. And for those whose lives and life's work are transformed by our fluid management technologies, the new well is everything. Nuwellis is headquartered in Eden Prairie, Minn., with a wholly-owned subsidiary in Ireland. The Company has been listed on the Nasdaq Capital Market since February 2012, previously branded as CHF Solutions (Nasdaq: CHFS).

Nyxoah is a pioneering medical device company developing a breakthrough therapeutic solution for the treatment of Obstructive Sleep Apnea (OSA). Our mission is to become a world leading company by offering unique patient-centric neuromodulation solutions, developed by passionate and exceptionally driven people Nyxoah's therapy Genio® offers: - Unparalleled clinical efficacy - Increased patient comfort, therapy compliance and quality of life - Minimally invasive approach, thus streamlining patient flow and reducing surgery related risks - Positive health economics outcomes by reducing the burden of OSA and its comorbidities

Okami Medical, Inc. is a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention.

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical's lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.

Orthofix is a global medical technology company headquartered in Lewisville, Texas. By providing medical technologies that heal musculoskeletal pathologies, we deliver exceptional experiences and life-changing solutions to patients around the world. Orthofix offers a comprehensive portfolio of spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including the 7D FLASH™ navigation system. 𝗢𝘂𝗿 𝗩𝗶𝘀𝗶𝗼𝗻: To be the unrivaled partner in MedTech, delivering exceptional experiences and life-changing solutions. 𝗢𝘂𝗿 𝗠𝗶𝘀𝘀𝗶𝗼𝗻: We provide medical technologies that heal musculoskeletal pathologies. We enable our teams through opportunities for growth, ownership of responsibilities, and empowerment to execute. We do this for patients and the healthcare professionals who treat them. We collaborate with world-class surgeons and other partners to bring to market highly innovative, cost-effective, and user-friendly medical technologies through excellent customer service. We do this to improve people’s quality of life and, in doing so, create exceptional value for our customers, employees, and stockholders. 𝗢𝘂𝗿 𝗩𝗮𝗹𝘂𝗲𝘀: • Take Ownership • Innovate Boldly • Win Together Join our mission to revolutionize musculoskeletal care and be a part of innovation that changes lives. Start your journey now at https://orthofix.com/about/careers/.

OrthoPediatrics is an Indiana-based bio-science company that designs and develops orthopedic implants and instruments for pediatric conditions.

A device from OtoNexus Medical Technologies uses air-coupled ultrasound technology to accurately assess middle ear infections, and in particular to differentiate when and when not to prescribe antibiotics.

Helping people maintain or regain their freedom of movement – this is Ottobock’s mission. Just as it has been for over 100 years. Our med-tech company continually sets new standards in the fields of prosthetics and orthotics. In 1997, we launched the C-Leg, the world’s first leg prosthesis to be controlled completely by microprocessors. Our C-Brace mechatronic orthosis, which helps people to stand and walk again when they are affected by paralysis due to neurological conditions such as multiple sclerosis and strokes, still features absolutely unique technology. And our portfolio also features wheelchairs and exoskeletons. The latter relieve strain for people who do physically demanding jobs and make workplaces in the industrial, logistics and trade sectors more ergonomic. Tech, digital, human – Ottobock creates an integrated approach by combining innovative products with customised treatment. The company has over 240 of its own patient care centres worldwide, ensuring close relationships with users and providing key momentum for the improvement of existing solutions and the development of new ones. As we move forward with the digitalisation of the fitting process, we are boosting efficiency and making our treatment more comfortable – for external orthopaedics companies and medical supply companies as well. We have maintained a stable growth track for many years, and our sales topped the one billion mark for the first time in 2019. Our over 8,000 employees worldwide contribute to achieving this. We coordinate our international activities from our headquarters in Duderstadt, Germany. Thanks to a global network of research, production and logistics sites as well as sales and service companies in over 50 countries, we combine a genuine international approach with a local presence. Data Privacy, Imprint, Legal Terms - Visit www.ottobock.com/socialmedialinks 

PathMaker Neurosystems is a near-commercial stage neuromodulation company founded to commercialize recent advances in the development of non-invasive devices for the treatment of patients with serious neurological conditions. The company's technology is based on the premise that electrical fields can be used to stimulate the nervous system in a non-invasive manner, offering the potential to treat a wide range of neurological disorders.

Penumbra is a medical devices company that specializes in neurovascular products and healthcare technology.

We are on a mission to build a comprehensive product portfolio dedicated to women's intimate health. Our approach is rooted in the ability to diagnose, treat, and prevent concerns, blending science with aesthetically appealing and beautiful products. We firmly believe women's intimate care should be grounded in scientific exploration. This commitment to research ensures that our products are effective and backed by a robust foundation of research and knowledge. Join us on a movement to redefine women's intimate health.

Developing innovative catheter technology to treat acute ischemic stroke, providing superior clinical outcomes in shorter procedural times.

Perosphere Technologies is focused on bringing forth new, Point-of-Care (PoC) solutions that make diagnosis, treatment, and prevention a matter of actionable data. We bring the clarity and confidence needed to transform an incomplete clinical picture and drive the way decisions are made in coagulation.

Welcome to the Phagenesis LinkedIn page!  At Phagenesis, we are dedicated to transforming the way dysphagia is treated. Dysphagia, or difficulty swallowing, can be a debilitating condition that affects millions of people worldwide. We believe that everyone deserves the ability to enjoy their meals and live their lives to the fullest, which is why we have developed the Phagenyx - a revolutionary product that uses Pharyngeal Electrical Stimulation (PES) to treat dysphagia.  The Phagenyx is a simple, non-invasive device that stimulates the nerves in the pharynx, helping patients regain control of their swallowing function. Our product has been rigorously tested in clinical trials and has been shown to significantly improve swallowing ability in patients with dysphagia.  As a company, we are committed to advancing the field of dysphagia care through innovative technology and evidence-based practices. We work closely with healthcare providers and patients to ensure that our product meets the highest standards of safety and efficacy.  We are proud to be changing the paradigm of dysphagia care, and we invite you to join us in our mission to improve the lives of millions of people around the world. Follow our page to stay up-to-date on the latest news and developments in dysphagia care, and to learn more about the Phagenyx and how it is helping patients overcome dysphagia.

Pi-Cardia is a medical device company and market leader in the development of a broad portfolio of leaflet modification solutions for treating heart valves. The company has years of knowledge and expertise accumulated in degenerated valves, including calcification patterns, mode of valve failure, and impact of various methods of leaflet modification. ShortCut™ is designed to provide a safe, simple, and effective way to split leaflets of a pre-existing valve to enable TAVR in patients at risk for coronary obstruction and may assist in preserving coronary access.

Podimetrics is the creator of the SmartMat™ and integrated clinical and patient support services that can help save the limbs and lives of patients living with complex diabetes. We provide high-risk patients our SmartMat™ through partnerships with payers and at-risk providers, including the Veterans Health Administration. After placing their feet on the mat for just 20 seconds a day, patients’ data are automatically sent to our care management team, which helps address any concerning findings. By combining cutting-edge technology with best-in-class care management, Podimetrics earns high engagement rates from patients and allows clinicians to achieve unparalleled outcomes — keeping vulnerable patients healthy at home and saving limbs, lives, and money. Founded in 2011 by a physician and engineers from MIT and Harvard, Podimetrics is headquartered in Somerville, M.A., and backed by Norwich Ventures, Scientific Health Development, Polaris Partners, and Rock Health. For more information, go to www.podimetrics.com or follow us on Twitter @podimetrics.

We are a clinical-stage, privately held medical technology company developing a transformational neuromodulation platform to treat diseases of undesired neural activity.

PROCEPT BioRobotics is a medical robotics company that specializes in minimally invasive robotic surgery technology.

Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix™ is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system. Aortix™ is currently in the research and development phase and is not available for sale in any country. (Caution: investigational device. Limited by federal law to investigational use.)

Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The people at Pulse Biosciences are some of the top experts in pulsed electric field technologies and have a broad range of engineering expertise across multiple medical device domains and will utilize nsPFA™ technology to treat a variety of applications for which an optimal solution remains unfulfilled. We have a deep and broad IP portfolio with over 130 issued patents globally owned and licensed. With this growing patent portfolio surrounding our innovative technology, Pulse Biosciences seeks to aggressively realize the potential of Nanosecond Pulsed Field Ablation technology by building a rich pipeline of transformative commercial applications.

We're a small but rapidly growing neurotechnology company based in Durham, North Carolina. Our vision is to enable and support outstanding basic and translational neuroscience research through innovative and affordable products. We launched XCSITE 100, our tDCS/tACS research solution, in 2016. Today, XCSITE 100 is used in leading brain stimulation labs across the United States. We are actively developing new technology and working with our stakeholders to provide new research solutions to enable cutting edge neuroscience.

A Canadian based medical device company building world's first minimally invasive heart pump for patients with advanced heart failure.

Quantum Surgical is a French company founded in Montpellier, France, speacialized in medical robotics and AI. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

Radialis is advancing precision medicine by providing the next generation of organ-targeted positron emission tomography (PET).

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Aspiration System*, which includes a novel aspiration pump and catheters to allow rapid and consistent removal of blood clots from the brain. The RapidPulse logo and the word mark RapidPulseTM are trademarks of RapidPulse, Inc., and are the subject of applications pending in the United States and internationally. *The RapidPulseTM Aspiration System is not cleared for sale in the United States.

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

An RPM Business Augmented by R&D Respiri Limited (ASX:RSH, OTCQB:RSHUF) is a pioneering presence in the Remote Patient Monitoring (RPM) and MedTech sectors. The company uses its innovative respiratory technology with a disruptive business model as an RPM provider to offer the only RPM program for respiratory disorders. As a differentiated RPM provider, Respiri's mission is to improve health outcomes for patients with chronic diseases from cardiovascular, diabetes, obesity and, exclusively, respiratory disease. Respiri's globally unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled. Respiri is strategically positioned to revolutionise chronic disease management globally and is focused on the US market, where RPM services are reimbursed by Current Procedural Terminology (CPT) Code reimbursement.

restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties. Leveraging expertise and experience in 3D printing of key biomedical materials spanning a wide range of properties, restor3d seeks to improve medical device solutions.

Our mission at Restore Medical is to provide a unique solution for patients with congestive heart failure (CHF). CHF is one of the leading causes of death and hospitalization, affecting millions worldwide. Patients remain with disabling symptoms despite receiving currently-available optimized medical treatment. To that end, we have developed ContraBand™, a novel catheter-delivered implant which aims to improve CHF patients’ quality-of-life and reduce hospital readmission rates.

REVA Medical, LLC. is a leader in bioresorbable polymer technologies for vascular applications. REVA's lead product, Fantom Encore, is a drug-eluting bioresorbable scaffold for the treatment of coronary artery disease. Fantom Encore is made from Tyrocore, REVA’s proprietary tyrosine derived polymer. Unlike metallic stents, Fantom Encore is designed support the artery through the healing process, and then disappear (or “resorb”) from the body in order to restore natural function to the artery. Learn more at www.revamedical.com.

RevBio was started with one goal in mind—to end medicine's 50 year search for a biocompatible bone adhesive. Effective for bone-to-bone as well as bone-to-metal wet field applications, Tetranite® is a revolutionary biomaterial that promises to transform bone repair—for both patients and clinicians. Inspired by the marine animal the sandcastle worm, Tetranite is simple chemistry. Bioengineered from the worm's secreted protein, our synthetic adhesive is the only patented biomaterial which satisfies both the required and desired properties for a bone adhesive: wet field performance, multi-surface bonding, rapid mechanical stability, and controlled biodegradability. The properties of Tetranite™ include the ability to provide immediate fixation of bone to bone and bone to metal. This adhesive has been shown in multiple animal studies to be a non-toxic and effective way of repairing bone fractures and defects as well as securing implant devices. Existing data has also shown that Tetranite™ is reabsorbed and replaced with new bone during the natural process of bone remodeling by acting as a scaffold to facilitate bone growth over time.

Rhaeos is a VC backed, clinical stage medical device company developing FlowSense, a platform technology and a noninvasive wireless, wearable skin patch that can assess and monitor fluid flow subdermally throughout the body. The company is initially targeting hydrocephalus, a life threatening condition caused by an abnormal accumulation of cerebrospinal fluid (CSF). Implantable shunts, the gold standard treatment, often fail, leading to multiple trips to the emergency room and repeat surgeries. There is no technology available today that can easily assess CSF flow in shunts wirelessly, bedside, and without capital equipment until now with FlowSense. FlowSense, is a proprietary wireless, wearable, and noninvasive sensor that can be mounted on skin overlying the shunt to detect the presence and magnitude of CSF. Its miniaturized, thin construction is similar in size to a bandage, and it is composed primarily of soft, silicone rubber with no hard edges. Data is wirelessly transmitted to a custom designed mobile app. Rhaeos received FDA breakthrough designation for FlowSense, is NIH and NSF funded (>$7.5M), published clinical data in Science and Nature family journals, and is on track for initial market entry in 2024. To date, the company has brought in >$19M in dilutive and non-dilutive financing. Follow on products for other chronic conditions are currently in development.

RTI Surgical (RTI) is a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. We are expert partners to Original Equipment Manufacturers (OEMs), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. We focus on specialized clinical segments, including breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery. Our Mission is to enhance patients' lives by creating the best clinical outcomes through innovative, high-quality medical solutions.

RxFunction®, Inc. is a medical device company with a mission to design and market medical technologies that improve balance, increase mobility, and enhance confidence for patients. Walkasins® Lower Limb Sensory Prosthesis is clinically proven to improve gait and balance, and reduce the risk of falls. Walkasins replaces part of the lost nerve function for the feet. It is intended for individuals who experience numbness in their feet and struggle with mobility problems due to peripheral neuropathy. Walkasins is only available by prescription. To learn more, please visit us at www.rxfunction.com. RxFunction created Walkasins by building upon patented technology developed by co-founder and scientist Lars Oddsson, PhD. Development of Walkasins was supported by Small Business Innovation Research grants from the National Institutes of Health and is manufactured in Minnesota. RxFunction is the exclusive provider and manufacturer of Walkasins. Caution: Individual results and activity levels while using Walkasins may vary depending on many factors. There are risks associated with the use of this product and there are certain individuals who should not use the product. Only a qualified clinician can tell you if this product is appropriate for you and your individual circumstances. Please consult with your healthcare team for complete information regarding benefits, risks, and possible outcomes.

Established in 2015 and based in France, SafeHeal™ is a clinical stage medical device manufacturer. Specializing in the development of anastomosis protection devices for colorectal surgery, SafeHeal's premier device, Colovac, was invented by French surgeon Charam Khosrovani to eliminate the need for diverting ostomies in patients undergoing colectomy.

Salvia BioElectronics is pioneering neuromodulation therapy aiming to transform the migraine treatment landscape. Designed to provide meaningful relief, MySalvia Therapy features an ultra-thin implant that comprehensively targets key nerves involved in migraine. ‍Salvia is driven by the belief that people with chronic migraine deserve the opportunity to reclaim their lives. Founded in 2017 and headquartered in Eindhoven, The Netherlands, Salvia is led by a team of industry veterans with extensive experience in medical devices and neuromodulation. Active in the United States, Europe and Australia, the company is advancing clinical development with the support of leading investors. Salvia is also exploring the potential of its technology for the treatment of cluster headache.

Sana is a digital heath company driven by 25 years of research into relief for symptoms of chronic pain and insomnia. Sana is developing the first non-invasive, comfortable bio-therapeutic device capable of inducing a deep restorative state of relaxation to alleviate pain and tension. The device provides relief in just 10 minutes through the use of audio-visual neuromodulation, and is currently undergoing FDA certification and clinical trials.

SecondWave Systems is a pioneer in the emerging field of bio-ultrasonic medicine. The company is developing a first-of-its-kind noninvasive, wearable ultrasound stimulation platform that will give patients and their physicians a new option for treating debilitating or life-threatening disease.

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM"​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Sensimed SA, a Swiss company, has developed a unique technology platform on non-invasive soft contact lens-based solution. The first application, the SENSIMED Triggerfish®, provides an automated recording of continuous ocular dimensional change over 24 hours with the aim of revolutionizing glaucoma management enhancing personalization of patient care. The SENSIMED Triggerfish® received the CE mark in 2010 and was approved by the U.S. Food and Drug Administration (FDA) in 2016. Since 2018 the device is registered in Japan at the Pharmaceuticals and Medical Devices Agency (PMDA). Other non-invasive on-eye sensing applications are in development to provide clinically pertinent data with the same continuous monitoring approach. The Company is furthermore focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The data, analysed and modeled on an ongoing basis, is processed in an attempt to identify pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy of treatment. The Company is directly positioned at the convergence between devices, treatment and information. Sensimed believes that with this global knowledge-based approach it will be possible to provide valuable insights that allow ophthalmologists to better understand and treat glaucoma. Sensimed became a subsidiary of SEED CO., Ltd after the acquisition of a majority participation end of 2019.

Sequana Medical NV is a pioneer in treating drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. Fluid overload is a well-recognized problem in these growing diseases, causing severe problems for the large number of patients for whom current medicines are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, causing major medical issues including increased mortality, repeated hospitalizations, severe pain, difficult breathing and restricted mobility that severely impacts daily life. alfapump® and DSR® are Sequana Medical's proprietary approaches that work with the body to remove this excess fluid, delivering major clinical and quality of life benefits for patients and reducing costs for healthcare systems. Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

Shape Memory Medical is dedicated to developing innovative embolization solutions for peripheral vascular, cardiovascular, and neurovascular markets. We are the first medical device company to introduce an FDA-cleared medical device utilizing shape memory polymer (SMP) technology (smart polymer) to a vascular market. We look towards what lies ahead, as we develop an aortic portfolio to address clinical needs and shape the future of sealing and healing.

ShiraTronics is a forward-thinking medtech startup committed to revolutionizing the field of migraine medicine with our minimally invasive neuromodulation system. Our mission? To transform the lives of those facing Chronic Migraine by reducing headache days and restoring quality of life.

The simplicity of our design--born out of our extensive experience--comes down to the basic notion that traditional fixation techniques aren't strong enough and don't last. Our InSet™ approach to Glenoid fixation is revolutionizing shoulder arthroplasty and, more importantly, improving procedure longevity--ultimately changing patient's lives.

Sibel Health, through engineering excellence, will deliver Better Health Data for All by developing soft, flexible sensors that are powered by advanced analytics, operated by best-in-class software, and integrated with the cloud optimized for artificial intelligence and machine learning.

Siemens Healthineersenables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare.COVID-19: CE mark for its molecular Fast Track Diagnostics (FTD)SARS-CoV-2 Assay.

We are committed to meeting clinical unmet needs in interventional cardiology through innovations in visualization, intelligence and automation

Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. The company is a spin-off of the Netherlands Cancer Institute, where researchers recognized the need to simplify and improve localization technology for the surgical removal of breast cancers. This led to the development and clinical demonstration of the first magnetic seed localization, a technique that Sirius Medical perfected and further developed into the Sirius Pintuition System. Today, Sirius Pintuition represents the next generation of tumor localization technology, known as Surgical Marker Navigation. Pintuition is the only wire-free localization technology designed to provide navigational guidance in an easy-to-use and intuitive system. Its state-of-the-art GPSDetect™ software and unique TargetLOC™ feature provide real-time directional guidance using audio and visual feedback for unmatched precision to locate tumors more efficiently and accurately. The Pintuition platform is simple, precise, and accurate, delivering a better experience for patients and physicians. The CE-marked and FDA-cleared system is currently available in over 200 centers in the United States and western Europe.

Solid Biosciences (Solid) is a life science company singularly focused on solving Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients.

Sommetrics, a privately funded company based in San Diego, develops products and services to treat airway problems that arise during medical procedures and during sleep. The company’s products are based on its patented aer+ technology, which uses negative pressure to hold a patient’s airway open through a comfortable, well-tolerated and non-invasive mechanism. For more information, visit www.sommetrics.com and follow the company on Twitter, Facebook and LinkedIn.

Sonavex, Inc. is a Baltimore-based medical device company originally spun out of Johns Hopkins focused on Empowered Patient Care. The company has developed a portfolio of novel ultrasound solutions that empower patient care by delivering critical visual and quantitative data to improve outcomes and reduce costs. EchoMark is a bioresorbable and highly echogenic (visible under ultrasound) implant used to mark at-risk blood vessels such that the site can be easily assessed for future complications. EchoSure is a deep-learning enabled 3D automated ultrasound device designed to be used by healthcare providers without ultrasound training to assess blood flow and morphology of vessels marked by the implanted EchoMark device. For more information, please visit http://www.sonavex.com

Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur offers real-time, AI guided quantification of the two key markers for fatty liver disease: liver stiffness and attenuation. With real-time results, a low up-front cost and AI guidance, VELACUR makes liver imaging at the point of care affordable and accessible.

Sonomotion is a medical device startup developing non-invasive solutions for the treatment of kidney stones. The company's stone repositioning and fragmentation solutions are currently in clinical trials in the U.S. and Canada.

Sooma Oy is developing, manufacturing and marketing a non-invasive therapy devices for neurological and psychiatric disorders (depression and chronic pain). Sooma uses transcranial direct current stimulation (tDCS) technology. Our technology is trusted by over 150 clinics worldwide. We feel that everyone deserves high quality care. With our Sooma therapies, we want to provide an effective and safe way to treat disorders within psychiatry and neurology. We want to offer a safe, drug-free treatment option with minimal side effects, that minimises any discomfort that might otherwise come with treating certain disorders. We want to ensure that medical professionals have access to a treatment option for patients which relieves symptoms without any fear of addiction or dependency. Our mission is to make our therapies an available and accessible option for all who may benefit from them. This includes patients who are unable to visit a clinic, but would benefit from a home-based treatment that does not compromise safety. Our first product is the first portable device approved for treatment of major depressive disorder (MDD). The device is CE-approved and currently marketed in the EU and other markets. Our quality management system has been awarded with ISO 13485:2016 and MDSAP certificates.

SoundBite is a medical devices start-up, Montreal and Sherbrooke-based, developing and commercializing proprietary shockwave device and generator technology delivered within the cardiovascular system to treat chronic total occlusions (CTO's). The company will target CTO's in patients with peripheral artery disease (PAD) and coronary artery disease (CAD), disease states that affect over 12 million and 8 million Americans, respectively.

Founded in 2003, Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

Starkey is a privately held, global hearing technology company headquartered in Eden Prairie, Minnesota, USA. We are recognized for our innovative design, development and distribution of comprehensive digital hearing systems. We develop products using an evidence-based design approach, meaning that rigorous testing takes place to prove the benefits of a new technology or algorithm before a hearing aid is ever fit on a patient. Every Starkey employee is committed to helping people on their journey to better hearing every day. Starkey operates 25+ facilities and conducts business in more than 100 markets worldwide. We develop, manufacture and distribute hearing aids via three distinct brands - Audibel, NuEar and our original brand, Starkey. Learn more about us on our blog: www.starkey.com/blog

Stimdia Medical, Inc., is a privately held company headquartered in Minneapolis, MN and has developed the pdSTIMTM System, a minimally invasive, temporary, neuromuscular stimulation system which has received FDA Breakthrough Device Designation. Mechanical ventilation (MV) is considered to be a lifesaving treatment in patients suffering respiratory failure to achieve sufficient pulmonary gas exchange. However, prolonged MV can promote atrophy and contractile dysfunction of the primary muscle utilized in respiration, the diaphragm. Significant loss in muscle mass results in a reduction in diaphragmatic function and compromises the ability of patients to breath on their own. The pdSTIM System was designed to awaken and restore the integrity of the diaphragm muscle in patients who are on MV. This is accomplished with the use of subcutaneously inserted temporary leads connected to the pdSTIM console and utilizes the proprietary RespiSyncTM sensing and stimulation algorithms to coordinate phrenic nerve stimulation with physiologic diaphragmatic movement in synchrony with mechanical ventilators. The pdSTIM System has not yet received regulatory clearances or approvals and is not currently for sale in any country.

Supira Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.

Synapse Biomedical Inc (SBI) was founded in September 2002 to commercialize the NeuRx Diaphragm Pacing System (DPS)® that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency. This innovation allows the technology to meet clinical needs, beyond the ability of the currently available systems, in Spinal Cord Injuries, in the diaphragm conditioning in muscular dystrophies (such as ALS) and in respiratory short-term intensive care settings.

At Synaptrix, we are pioneering accessible technologies to empower individuals with paralysis to live more independently. Our first device, Neuralis™, is a non-invasive, EEG based neural interface that allows paralyzed individuals to control the wheelchair they already use with their brain activity and eye movements. By interpreting signals from visual cortex, Neuralis™ enables intuitive and effortless wheelchair navigation. Neuralis™ is specially designed to meet the needs of paralyzed patients with conditions like ALS, spinal cord injury, MS, strokes, and other neurodegenerative conditions. It provides an affordable alternative to complex, expensive solutions that are often impractical for daily independence. At Synaptrix, we are committed to improving the quality of life for individuals with physical limitations. Through our research, we seek to contribute to the advancement of assistive technologies for patients with neurological conditions, emphasizing the importance of regaining autonomy and control over their lives.

Synchron is a Brain Computer Interface company based in Campbell, California and Melbourne, Australia. We are developing minimally-invasive technology for safe and rapid implantation of miniaturized electronic medical devices with broadband capability.

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem is the #1 recommended insulin pump brand by people living with diabetes, four years and counting. (dQ&A US Diabetes Connections Patient Panel Report; Net Promoter Score; Q1 2019-Q3 2023: P.49, Q3 2023 (Jan. 2019-Sept. 2023). Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com. SAFETY INFORMATION Please note that this account is not intended to be used for product support or medical advice. If you are having a medical emergency, please dial 911. If you are having an issue with one of our products and need immediate assistance, please call our 24-hour customer support team at 877-801-6901 and press 1 twice. RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. Safety info: tandemdiabetes.com/safetyinfo.

Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.

TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for the treatment of ocular surface disease in primary Sjögren’s Syndrome patients. Statistically significant improvement in both sign and symptom at two weeks was found. The trial compared vehicle and two doses of LacripepTM, a novel 19 AA peptide that is present in normal tears and deficient in all forms of dry eye. The peptide restores homeostasis to the ocular surface, in particular the barrier function of the corneal epithelium and normal function of sensory nerves at the corneal surface in preclinical animal models. Restoration of epithelial barrier function can be measured clinically as a decrease in corneal fluorescein staining while the improvement in sensory nerve function restores normal production of the components of tears: the aqueous via reinnervation of lacrimal glands, the lipid via reinnervation of meibomium glands and the mucin via reinnervation of goblet cells. Improvement in fluorescein staining and tear production (Schirmer tear test) are clinical ‘signs’ of ocular suface disease that have been used in the FDA approval of Xiidra and Restasis, respectively. Lacripep was discovered at the University of Virginia with NIH National Eye Institute funding as a naturally occurring fragment of the larger 119 AA protein, lacritin, in an unbiased screen for novel factors capable of addressing dry eye.

Tempo Therapeutics is a biotechnology company that specializes in tissue engineering using proprietary MAP material science technology to build functional tissue and organs within patients in real time for disease treatment.

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It's About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

Since 2011, Tenex Health has pioneered minimally invasive relief for chronic tendon pain with a one-time ultrasonic treatment. Since 2012, more than 100,000 procedures using the Tenex Health TX technology have been performed. The device is designed for the removal of diseased soft and hard tissue and restoration of healthy musculoskeletal function. Our mission is to provide patients who suffer from chronic tendon pain with a minimally invasive solution to remove the cause of their suffering and get them back to the things they love and need to do with less downtime than traditional treatment methods or surgery. Using conventional ultrasound guidance and the breakthrough Tenex Health TX System, surgeons can quickly and precisely treat only the damaged tendon tissue, leaving the surrounding healthy tendon unharmed. Because the procedure uses ultrasonic energy applied with the TX MicroTip and typically no stitches or general anesthesia are required, there is minimal downtime. Individual results may vary. For more information, visit www.TenexHealth.com.

Located in San Francisco CA, TheraNova is a medical device development company focused on developing solutions to large markets with unmet needs. TheraNova accomplishes this through its mission to improve outcomes, decrease costs and expand access to healthcare.

Thrombolex is engaged in the design, development, and distribution of innovative endovascular catheters used in interventional procedures, particularly in pharmaco-mechanical catheter-directed thrombolysis (PM-CDT) in patients who suffer from arterial and venous thromboembolic (A&VTE) conditions. The Company is currently marketing seven (7) different FDA-cleared devices that are all based on the BASHIR™ Endovascular Catheter platform technology.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans1, of which Treace estimates 1.1 million are annual surgical candidates. Treace Medical has pioneered and patented the Lapiplasty® 3D Bunion Correction® system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause2,3 of the bunion. At Treace Medical Concepts, Inc., our mission is to advance the standard of care for the surgical management of bunions and related midfoot deformities. Treace Medical offers the Adductoplasty® System, the Hammertoe PEEK Fixation System, the SpeedPlate™ System, and other ancillary The content herein is for informational purposes and intended for healthcare professionals only. Treace Medical Concepts, Inc. does not dispense medical advice. A surgeon should rely on his or her own professional clinical judgment when deciding whether to use a specific product when treating a particular patient. Prior to use of the device, the surgeon should refer to the instructions for use for complete indications, contraindications, warnings, and risks. Complete risk and benefit information: www.treace.com. Visit www.treace.com/privacy-policy for our Privacy Policy. Treace Medical will make an offer of employment only to individuals who have applied for a position using our official application. Be on alert for possible fraudulent offers of employment. Treace Medical will not solicit money or banking information from applicants. 1Nix S, et al. J Foot Ankle Res. 2010. 27:3:21. 2Dayton P, et al. J Foot Ankle Surg. 2016;55:567-71. 3Dayton P, et al. J Foot Ankle Surg. 2018;57:766-770.

Uptake Medical® developed innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor®, was the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. Uptake Medical was acquired in July 2016 by Uptake Medical Technology Inc, a subsidiary of Broncus Holding Corp.

Valencia Technologies is a neuromodulation company transforming the standard of care for bladder dysfunction. The coin-sized electroceutical - eCoin® - is a radically small neurostimulator that automatically provides safe and effective treatment for Urge Urinary Incontinence. It has the experienced leadership of Jeff Greiner and the talented team to bring this platform medical device to market for the treatment of various chronic conditions. The company arose from the discovery that more scientifically verifiable work was being done in acupuncture and that there was a place for neuromodulation to further advance the work. Valencia designed and developed the eCoin® for the treatment of major chronic conditions. Engineered and designed by Dave Peterson and Chula Thenuwara, the eCoin® is unique as a leadless device that is 1/8th the size of the smallest pacemaker-like device on the market. For more information on Valencia and the current offering, please visit our website at www.valenciatechnologies.com

Vapotherm, Inc. is the inventor of high flow nasal cannula, and its advanced form: Vapotherm high velocity therapy. Delivering high velocity therapy, the Precision Flow® system offers clinicians a reliable tool for multiple patient populations. For respiratory distress patients presenting in the ED and ICU, high velocity therapy can provide not just oxygenation, but also Mask-Free respiratory support with the comfort of heated humidified high flow. Vapotherm, Inc. is a publicly traded company and its common stock trades on the OTCQX tier of the OTC Markets under the symbol "VAPO".

Verily is an Alphabet company combining a data-driven, people-first approach to bring the promise of precision health to everyone, every day. We are focused on generating and applying evidence from a wide variety of sources to change the way people manage their health and the way healthcare is delivered - shifting the paradigm from “one size fits all” medicine to one focused on a more comprehensive view of the individual that leads to a more personalized path forward. For more information, please visit verily.com. Verily is hiring! Check out what's available globally at verily.com/careers.

Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over 200 patents and patent applications, the company is developing MIRA, the first-of-its-kind miniature, and highly accessible RAS platform. With MIRA, our goal is to make every operating room RAS-ready. MIRA is currently in FDA clinical trials under an Investigational Device Exemption (IDE) and is being studied first for bowel resection, with additional potential applications to follow. https://virtualincision.com

Vitestro will be the first to bring autonomous blood drawing technology to European hospitals. Blood drawing, performed billions of times per year worldwide, is key to clinical diagnosis. Given a growing population and shortages of healthcare personnel, there is a clear need for a future-proof system to keep up with demand for diagnostics.

The company develops advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery.

V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave's vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company's senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.

At Vyaire, we know that each patient has different goals—and every breath counts to achieve them. We are a company on the move, relentlessly innovating, challenging the status quo and keeping patient needs at the forefront of everything we do to enable, enhance and extend lives. Established from legacy brands with a 70-year history of pioneering breathing technology, Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. We pledge to evolve what’s possible to ensure every breath is taken to its fullest. We pledge to evolve what’s possible to ensure every breath is taken to its fullest. We accomplish this through our values: Patient Purpose, Customer First, Employee Success, and Corporate Integrity. The company’s origin began in the 1950s with the invention of the first mechanical ventilator and has since brought together well-known brands with proven track records of pioneering and advancing respiratory diagnostics and ventilation. Formed in 2016, the unified Vyaire established the world’s largest consortium of experts and industry leaders solely focused on the breathing continuum for customers and patients across the globe. Our passionate, dedicated global workforce consists of experienced breathing specialists who are inspired and empowered to elevate the quality of each inhale and each exhale. Vyaire acknowledges and celebrates the individual backgrounds, perspectives, and voices of our team members to best serve the diverse needs of patients and healthcare providers. Bring your unique talents, commitment, and career aspirations to our global team of dedicated professionals. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Minimally Invasive Technology for Obstructive Sleep Apnea

The Xoft® Electronic Brachytherapy System® is an isotope-free radiation treatment cleared by the FDA for use anywhere in the body, including non-melanoma skin cancer, brain tumors, early stage breast cancer, and gynecological cancers. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System can be administered as a single course of radiation therapy during surgery in the form of intraoperative radiation therapy (IORT) or in the form of partial breast irradiation (APBI). The Xoft System does not require a shielded environment and the system’s relatively small size and mobility enable it to be used in virtually any clinical setting. A post-market study is underway to assess the safety and efficacy of IORT with the Xoft System. For more information about Xoft visit www.xoftinc.com.

Wisdom Sales + Marketing helps small and midsized food companies grow their business. We do this by providing food brokerage services representing food companies in National Retail and Food Service Restaurant Chains Accounts in North America. Many of our customers need more than just sales support to grow as a result we also provide management consulting in the areas of strategic planning, acquisition / divestiture support, ROI marketing analysis, sales and marketing structure and alignment, branding, innovation / product development, advertising, and consumer promotion. If you need help selling or buying a business, or raising capital we may also be able to help.

ZimVie is a global leader in dental implants and spine innovations. Advancing clinical technology foundational to restoring daily life.

ZOLL Medical is a medical devices company that specializes in healthcare technology for emergency response, with a focus on cardiac care and resuscitation.

Zynex, Inc. founded in 1996, engineers, manufactures and markets neuro-diagnostics, stroke rehabilitation, pain management and cardiac monitoring devices within three subsidiaries. Zynex Medical is a provider of electrotherapy products for home use. Zynex Monitoring Solutions develops products for cardiac monitoring for use in hospitals. Zynex NeuroDiagnostics develops devices for EMG and EEG diagnostic applications within neurology disciplines. Zynex Medical's product line is fully developed, FDA/CE cleared, commercially sold, and has been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex Monitoring Solutions and Zynex NeuroDiagnostics are currently both in the development stages without any significant revenues.